Oxbryta Lawsuit

The U.S. Food and Drug Administration (FDA) announced on September 26, 2024, that Oxbryta (voxelotor) is being withdrawn from global markets. The lawyers at Johnson//Becker, PLLC, are currently accepting new cases for clients who suffered adverse effects from Oxbryta, which was used to treat sickle cell disease.

Oxbryta Lawsuit
If a defective drug such as Oxbryta (voxelotor) harmed you or a loved one, you may want to speak with the lawyers at Johnson//Becker.

Sickle Cell Disease and Oxbryta (Voxelotor)

According to the FDA, Oxbryta is being withdrawn from the market due to safety concerns. Pfizer Inc., the manufacturer of Oxbryta, announced that recent data suggests the medication’s risks outweigh the benefits. Sickle cell disease (anemia) is an inherited blood disorder that causes abnormal hemoglobin production, resulting in rigid, sickle-shaped red blood cells that can block blood flow. It is estimated that this blood disorder affects roughly 100,000 people in the United States.

In 2019, the FDA approved Oxbryta for sickle cell anemia in adults and pediatric patients 12 years and older under the accelerated approval pathway. Accelerated approval is designed to expedite the availability of drugs that treat serious or life-threatening conditions. In 2021, the FDA granted accelerated approval of Oxbryta for patients aged 4 to 11.

In post-marketing clinical trials, Pfizer reported a higher rate of vaso-occlusive crises (VOCs) – severe pain caused by sickled red blood cells blocking blood flow and oxygen delivery to tissues – in patients who took the drug. VOCs are one of the most common complications associated with sickle cell disease. These VOCs cause severe pain that can lead to kidney failure, stroke, and death.  Pfizer reported eight deaths in the Oxbryta treatment group compared to two in the placebo group. Pfizer has halted production of Oxbryta (voxelotor) and ended clinical research on the product. It is uncommon for drugs to be withdrawn or recalled.

Questions About an Oxbryta Lawsuit? Contact a Johnson//Becker Lawyer for a Free Case Review

If a defective drug such as Oxbryta (voxelotor) harmed you or a loved one, you may want to speak with the lawyers at Johnson//Becker. We are currently monitoring this situation and investigating potential legal claims on behalf of patients and families impacted by this defective drug. We are currently taking new cases for Oxbryta nationwide, and you may be entitled to financial compensation.

We offer a Free Case Evaluation. Please use the form below to contact us or call (800) 279-6386. We would be honored to speak with you and respond promptly to every inquiry.

Free Case Evaluation

Verified 100% Secure Site To contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (800) 279-6386.
  • I understand by submitting this form that I am providing my consent to be contacted by Johnson//Becker, potentially using automated technology, at the number provided regarding my potential claim. I affirm that I am 18 years old or older and I consent to receive automated SMS text messages/calls. I understand and agree that by submitting this form I agree to the SMS Text Messaging Policy, Privacy Policy and Terms of Use and that this form does not create an attorney-client relationship.